Neurocrine Biosciences Inc vs Workday Inc — how do they compare? Neurocrine Biosciences Inc trades at $158.38 (market cap $16.46B), while Workday Inc trades at $174.4 (market cap $44.77B). The key difference: Workday Inc is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | WDAY | |
|---|---|---|
Market Cap | $16.46B | $44.77B |
Sector | Health | Technology |
52-Week High | $185.50 | $247.69 |
52-Week Low | $123.10 | $112.55 |
Enterprise Value | $16.48B | $44.22B |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Workday (WDAY) trades at $184.19, up 2.53% with strong technical momentum and consecutive earnings beats. The stock shows bullish moving average signals despite overbought RSI readings. Revenue growth accelerated to $8.45 billion in 2025 with improving net margins of 6.22%, while analyst consensus remains positive with 55.6% buy ratings. Recent partnerships and AI product launches demonstrate continued innovation in enterprise software.
Outlook remains constructive given consistent earnings outperformance and AI-driven growth initiatives, though elevated valuation multiples and institutional selling present near-term headwinds. Key risks include competitive pressures and execution challenges in enterprise software market transitions.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →